Loratadine

• Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting
  2022-500266-10-00 Phase III 12 countries Rheacell GmbH & Co. KG
• A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting
  2025-524580-21-00 Phase II/III 1 country Inmunotek S.L.
• A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting
  2025-522642-44-00 Phase II 4 countries Pfizer Inc.
• Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting
  2023-508520-36-00 Phase III 7 countries Allergy Therapeutics (UK) Limited
• A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended
  2024-515717-17-00 Phase III 1 country Inmunotek S.L.
• Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen a… Ended
  2024-511383-88-00 Phase II/III 1 country ROXALL Medizin GmbH
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended
  2023-504942-75-01 Phase III 6 countries HAL Allergy B.V.
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended
  2023-505880-35-00 Phase II/III 1 country ROXALL Medizin GmbH
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA… Ended
  2023-503830-27-00 Phase II 3 countries Allogene Therapeutics Inc.
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 Phase II 2 countries Allogene Therapeutics Inc.
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended
  2023-505567-37-00 Phase II/III 1 country ROXALL Medizin GmbH
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended
  2022-500121-33-01 Phase III 12 countries Hansa Biopharma AB
• Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM). Ended
  2024-516808-42-00 Phase II 1 country Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Showing 1–13 of 13 trials